NRIX

In the past six months, Nurix Therapeutics' stock has seen significant activity, with its share price increasing by 147.95% from $9.28 on September 29, 2025, to $23.01 on September 25, 2026. Following its earnings report on July 9, 2026, shares initially declined by 6.6% but subsequently drifted 1.6% higher, trading within a range of $21.23 and $28.23. Recent positive developments include the enrollment of the first patient in a Phase 1b/2 combination study of Bexobrutideg in Chronic Lymphocytic Leukemia on October 7, 2026, and a second research term extension for an oncology program under its collaboration with Gilead Sciences announced on October 5, 2026. The company also achieved a $7 million milestone under its strategic collaboration with Pfizer on September 29, 2026, and announced HSR clearance of its global collaboration with Roche to co-develop and co-commercialize Bexobrutideg in July 2026. As of October 9, 2026, the stock was trading below its 50-day moving average of $25.20 but remained above its 200-day moving average of $19.67. Despite a reported revenue growth decline of 79.50%, negative EPS of -$3.46, and a negative return on equity of -80.30%, analysts maintain a bullish outlook with a consensus price target of $33.93, suggesting a potential upside of 52.76%.